Shots: In the five-year follow-up data from the randomized POLARIX study, where participants received R-CHOP with a placebo for polatuzumab (control arm) and Pola-R-CHP with a placebo for vincristine The primary endpoint of the study was progression free survival, and the secondary endpoint was overall survival PharmaShots welcomes Dr. John Burke from Rocky Mountain Cancer…
